Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

Phase 2positiveenicepatidePositive

AI Analysis

Summary

Genentech announced positive Phase II results for enicepatide (CT-388), a dual GLP-1/GIP receptor agonist, in patients with Type 2 Diabetes and overweight or obesity. The trial (CT-388-104) met its primary endpoints.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Met

Outcome Details

Positive topline results from CT-388-104 Phase II clinical trial

Importance:7/10

Sentiment:

0.85

Phase II DataGLP-1/GIP Receptor AgonistType 2 DiabetesObesityPositive Results

Related Companies

$RHHBY

Read the original article

Published by Drugs.com Clinical Trial Results on September 21, 2026 8:09 PM

Read Original